HPTN 083: Long-Acting Injectable CAB Superior to Daily Oral TDF/FTC as PrEP in MSM and TGW at High Risk of HIV Infection

July 6-10, 2020; Virtual
Long-acting CAB injected intramuscularly every 2 months reduced the risk of HIV infection by 66% compared with daily oral TDF/FTC in high-risk MSM and transgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 294 KB
Released: July 11, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Download CCO slides reviewing current/emerging strategies for HIV prevention, including current PrEP options and novel delivery systems

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Gregory Huhn, MD, MPHTM
Released: March 3, 2021

Download expert-authored CCO slides reviewing data and guidelines on management of heavily-treatment experienced patients with HIV

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: March 3, 2021

Download expert-authored CCO slides reviewing data and guidelines on management of heavily-treatment experienced patients with HIV

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Released: March 2, 2021

CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Released: March 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue